Predicting the response of triple negative breast cancer to neoadjuvant systemic therapy via biology-based modeling and habitat analysis
Year: 2025
Type: article
Abstract: Despite being the standard-of-care treatment, neoadjuvant therapy (NAT) attains a complete response only in approximately half of the patients with triple negative breast cancer. Thus, methods to predict and optimize patient response to NAT are needed. Previously, we employed patient-specific MRI data to calibrate a biology-based mathematical model that describes cell movement, proliferation, and death due to drug at the tumor level and cell proliferation at an image voxel level. We now extend our approach by using MRI data to group voxels into "habitats" whereby tumor cells of a habitat share the same proliferation. With this approach, we now calibrate habitat-informed proliferation rates for each habitat rather than local proliferation rates. When comparing error in tumor cell number and volume at the time of calibration, the local calibration has significantly (p < 0.05) lower error than the habitat-informed calibration. However, the habitat-informed predictions of a future timepoint have significantly lower error than the local predictions. Compared to the local calibration, the habitat-informed calibration also requires fewer parameters, reducing the calibration time by a factor of 17. These results suggest that a habitat-informed calibration can provide both accurate and efficient predictions of breast cancer response to NAT.
Source: Scientific Reports
Language: English
Subfield: Modeling and Simulation
Field: Mathematics
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $2,690
Funders: National Science Foundation, Conquer Cancer Foundation, Amgen, Pfizer, Sanofi, Cancer Prevention and Research Institute of Texas, Gilead Sciences, University of Texas at Austin, Astellas Pharma, National Institutes of Health, Genentech, University of Texas MD Anderson Cancer Center, National Cancer Institute, National Science Foundation Graduate Research Fellowship Program
Awards: Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy, INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCER, G4267969883, Graduate Research Fellowship Program (GRFP), G6601967047, G946978917
OpenAlex ID: W4416718811
